Trials / Completed
CompletedNCT01620762
Phase III Cat-PAD Study
A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,408 (actual)
- Sponsor
- Circassia Limited · Industry
- Sex
- All
- Age
- 12 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the treatment effect of two treatment regimens of Cat-PAD vs placebo and to evaluates the treatment effect of Cat-PAD on symptoms, rescue medication usage and Quality of Life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cat-PAD | 1 dose every 4 weeks |
| DRUG | Placebo | 1 dose every 4 weeks |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2016-06-01
- First posted
- 2012-06-15
- Last updated
- 2018-06-15
- Results posted
- 2018-05-14
Locations
118 sites across 9 countries: United States, Belgium, Canada, Czechia, Germany, Hungary, Poland, Russia, Slovakia
Source: ClinicalTrials.gov record NCT01620762. Inclusion in this directory is not an endorsement.